Assessing Treatment Response in Patients With Myelofibrosis

Response is assessed in patients starting a JAK inhibitor by monitoring symptoms on a severity scale, spleen size, blood counts, and overall patient impression of change, with the goal being reduction of symptoms and stabilization of blood counts to improve quality of life.

CML Alliance
Enable registration in settings - general
Compare items
  • Total (0)
Shopping cart